Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer

Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer

Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death worldwide, with anaplastic lymphoma kinase (ALK) fusion mutations accounting for approximately 4%-9% of cases. In recent years, there are increasing clinical evidences suggesting that the combinati...

Full description

Saved in:
Bibliographic Details
Main Authors: Weizhen SUN, Yuheng ZHOU, Yaobin LIN, Shoucheng FENG, Hao LONG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2024-11-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
alk-positive
neoadjuvant therapy
targeted therapy
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2024.106.30
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items